Evidence map›Paper›PMID 39982033›Full record

ArticleJournal of virology2025

Changes in the dynamic characteristics of G-protein can alter the immune-protection efficacy of rabies virus vaccine.

Chang-Xu Chen, Xi Wang, Wen Su, Yuan Tian, Yu Gao, Dong-Lan Liu, Hong Xiang, Bo-Chuan Liu, Jin-Li Shi, Yang Zhang and 8 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Evolution of Zika virus inVirus evolution · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chang-Xu Chen *Bioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Xi Wang *Bioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Wen Su *Biological Product Batch Issuance Laboratory, Medical Products Administration of Yunnan Province, Kunming, China.
Yuan TianBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Yu GaoBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Dong-Lan LiuBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Hong XiangBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Bo-Chuan LiuBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Jin-Li ShiBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Yang ZhangBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Dong ShenBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Wen-Zhi HeBiological Product Batch Issuance Laboratory, Medical Products Administration of Yunnan Province, Kunming, China.
Li YangBiological Product Batch Issuance Laboratory, Medical Products Administration of Yunnan Province, Kunming, China.
Chao HongBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.
Fan WuBiological Product Batch Issuance Laboratory, Medical Products Administration of Yunnan Province, Kunming, China.
Lei-Tai ShiNational Institutes for Food and Drug Control, Beijing, China.ORCID 0000-0001-9713-8855
Yi-Na CunBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.ORCID 0009-0005-7023-0367
Jian ZhouBioproduct R&D Process Research Platform, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, China.ORCID 0009-0006-8902-6515

Funding

| Major Science and Technology Projects in Yunnan Province () 202402AA310019MOST | National Key Research and Development Program of China (NKPs) 2023YFC2307904
6 · The paper itself

Abstract

The efficacy of the G-protein is influenced by N-linked glycosylation, which serves as the sole immunogen of the rabies virus vaccine. However, achieving satisfactory immune-protection efficacy remains challenging, owing to the heterogeneous glycosylation of G-proteins. Within molecular dynamics, examining the impact of N-glycan heterogeneity on the structural characteristics of G-proteins provides insights into the relationship between antigens and the efficacy of rabies virus vaccines. Glycosylation is regulated by host cells. In rabies virus cultured in Vero cells (VRV), all N-glycosylation sites of the G-protein underwent modification. In contrast, rabies virus G-protein cultured in KMB17 cells (human diploid cell vaccine [HDCV]) was only modified by N-glycans at amino acid positions 247 and 319. Furthermore, treatment of VRV with de-glycosylation significantly improved its immune-protective efficacy, whereas de-glycosylation did not alter the immune-protective efficacy of HDCV. To support the impact of glycosylation on VRV efficacy, the structures and dynamics of G-proteins were analyzed using GROMACS. Specifically, the hydrophobicity, flexibility, and radius of gyration of the G-protein trimer in VRV were significantly altered by excessive hydrogen bonds formed by the three-branched hybrid glycan at the aa 319 site. These changes increase the instability of the G-protein trimer and may lead to a decrease in vaccine protective efficacy. Ultimately, we determined that N-glycan heterogeneity affects the immune-protection effect of antigen proteins by altering their dynamic characteristics, enhancing our understanding of the correlation between antigen structural characteristics and efficacy. IMPORTANCE: N-glycosylation of rabies virus glycoprotein dynamically regulates protein folding, stability, and antigenicity. Therefore, regulation of N-glycan modification is key to improving vaccine stability and protective efficacy. How the type and modification sites of N-glycans affect the protective efficacy of rabies vaccines remains unclear. Our research indicates that there are differences in the protective efficacy of rabies virus G-proteins modified with different N-glycans. Moreover, the modification of the three-branched hybrid glycan at the aa 319 site of G-protein significantly altered the hydrophobicity, flexibility, and radius, and increased its trimeric antigen instability through molecular dynamics demonstrations. These findings update the current understanding of the impact of glycans on vaccine antigenicity and develop a system to evaluate the stability of antigen glycoproteins based on molecular dynamics.

Indexed as

RabiesRabies VaccinesRabies virusViral Envelope ProteinsAnimalsAntibodies, ViralAntigens, ViralChlorocebus aethiopsGlycoproteinsGlycosylationHumansMiceMolecular Dynamics SimulationPolysaccharidesVaccine EfficacyVero CellsAntibodies, ViralAntigens, Viralglycoprotein G, Rabies virusGlycoproteinsPolysaccharidesRabies VaccinesViral Envelope ProteinsG-protein structureimmunogenicitymolecular dynamicsrabiesvaccines

Identifiers

PMID39982033
PMCPMC11915851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.